![]() ![]() Although they can’t process as much as the larger high-throughput systems, being smaller has its obvious advantages. Of the NGS systems, benchtop sequencers have a good niche currently. Next generation sequencing (NGS) systems are evolving rapidly, meaning this should be a core area of focus for a company should they want to excel now and in the near future. In a reply to BCC from one of the top sequencing industry leaders, George Church explains in more detail some of the technological specifics to success. In general, chosen companies have a solid foundation built around their sequencing technology and have done an excellent job strategically positioning themselves into one (or many) of the facets of the industry. But investment in seemingly rival efforts is also unusually high, underscoring both the connected nature of the research and commercial community, and also a “quantitative easing” or de-risking of being on the right team when the eventual winners are crowned in this high stakes field.įor this top 10 report, many factors were considered when selecting the companies. Certain individuals, such as Mike Hunkapller and George Church, appear and reappear in several of the leading companies as co-founder, adviser or board member. Of significance is the large occurrence of collaboration and co-ownership among the top players. It should be noted that sequencing costs may only contribute 10% to 20% of a typical biomedical projects overall costs. Each technology is analyzed to determine its market status, impact on future market segments, and future growth potential. This focused document profiles the top 10 companies of the industry and explores the underlying technologies driving the industry’s growth. Sequencing technologies are a critical part of today’s life-science industry, affecting a wide range of activity from drug discovery to diagnostics. The types of automation that enabled cost efficiencies in sequencing tools have become decision tree shortcuts in the clinic, whereupon the first tangible fruits from the promise of personalized medicine have become apparent.ĭNA sequencing is a strategic genomics tool that allows us to study how the genome varies among individuals and how that variation correlates to disease. ![]() When Watson and Crick let the genie out of the research bottle, it was inevitable that this day would arrive-the only question was when it would happen. Tandem repeats and retrotransposons have been conveniently converted into a “plus” or “minus” sign-a red light/green light clinical decision. The clinician does not need to understand the mathematical underpinnings of 16SrRNA coverage for phylogeny to run a rapid anthrax test. Recently, this story has begun to change as low cost next generation sequencing democratizes genome data, allowing a politics and commerce of inclusion, to enter the lab and now also the clinic.ĭiagnostic manufacturers can now afford to develop sequencing tools as diagnostic shortcuts. The narrative is understood by only those select few who have the cross discipline knowledge to comprehend what the sequencing tools output, and who also have the niche domain experience to act upon knowledge of that data. The story of molecular biology is being both written and printed by sequencing tools-various chapters being currently authored by oncologists, ID experts, pathologists, and so forth. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |